TLK-286.
Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.
Verschraegen
Claire F
CF
University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA. cverschraegen@salud.unm.edu
Smith
Harriet O
HO
Lee
Fa Chyi
FC
Cathcart
Cynthia
C
Norenberg
Jeffrey P
JP
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005978:Glutathione / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; C107479:TER 286; D005978:Glutathione